Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhBNP for Heart Failure After Acute Myocardial Infarction (Multimodal Observational Study)
ChiCTR2500108645Phase 4Recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nesiritide in myocardial infarction (MI) and Acute Heart Failure (AHF), sponsored by Shengjing Hospital of China Medical University. Primary endpoints: Heart failure readmission rate within 30 days and NT-proBNP levels at 72 hours. Started Sep 2025; status: recruiting.
02
Drugs
nesiritide
03
Conditions
myocardial infarction (MI)Acute Heart Failure (AHF)
Beyond the preview
Go deeper on ChiCTR2500108645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108645.